1-4 of 4
Victor E. Velculescu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B060: Dual blockade of BRD4 and the ATR/WEE1 pathway exploits ARID1A loss in clear cell ovarian cancer

Yasuto Kinose, Haineng Xu, Sushil Kumar, Hyoung Kim, Sergey Medvedev, Xiaolei Wang, Erin George, Xiaoyin Shan, Sarah Gitto, Kurt D'Andrea, Bradley Wubbenhorst, Margaret Whicker, Dorothy Hallberg, Lauren Schwartz, Katherine L Nathanson, Gordon Mills, Victor E Velculescu, Tian-Li Wang, Eric Brown, Ronny Drapkin, Fiona Simpkins
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B060.
https://doi.org/10.1158/1535-7163.TARG-23-B060
Published: 01 December 2023
View article titled, Abstract B060: Dual blockade of BRD4 and the ATR/WEE1 pathway exploits ARID1A loss in clear cell ovarian cancer
Journal Articles

Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness

Claudia Iavarone, Ioannis K. Zervantonakis, Laura M. Selfors, Sangeetha Palakurthi, Joyce F. Liu, Ronny Drapkin, Ursula A. Matulonis, Dorothy Hallberg, Victor E. Velculescu, Joel D. Leverson, Deepak Sampath, Gordon B. Mills, Joan S. Brugge
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (3): 642–655.
https://doi.org/10.1158/1535-7163.MCT-18-0413
Published: 01 March 2019
View article titled, Combined MEK and BCL-2/X<sub>L</sub> Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness
Open the PDF for Combined MEK and BCL-2/X<sub>L</sub> Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness in another window
Includes: Supplementary data
Journal Articles

Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors

Christopher A. Hamm, Diarmuid Moran, Kakuturu Rao, Patricia B. Trusk, Karen Pry, Mark Sausen, Siân Jones, Victor E. Velculescu, Massimo Cristofanilli, Sarah Bacus
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (7): 1746–1756.
https://doi.org/10.1158/1535-7163.MCT-15-0353
Published: 05 July 2016
View article titled, Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8<sup>+</sup>/PDL1<sup>+</sup> Immune Infiltration in Inflammatory Breast Cancer Tumors
Open the PDF for Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8<sup>+</sup>/PDL1<sup>+</sup> Immune Infiltration in Inflammatory Breast Cancer Tumors in another window
Includes: Supplementary data
Journal Articles

Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer

Maike Ihnen, Christine zu Eulenburg, Teodora Kolarova, Jing Wei Qi, Kanthinh Manivong, Meenal Chalukya, Judy Dering, Lee Anderson, Charles Ginther, Alexandra Meuter, Boris Winterhoff, Siân Jones, Victor E. Velculescu, Natarajan Venkatesan, Hong-Mei Rong, Sugandha Dandekar, Nitin Udar, Fritz Jänicke, Gerrit Los, Dennis J. Slamon, Gottfried E. Konecny
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (6): 1002–1015.
https://doi.org/10.1158/1535-7163.MCT-12-0813
Published: 09 June 2013
View article titled, Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer
Open the PDF for Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer in another window
Includes: Supplementary data